You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.

Happy Friday, Zingernation! Look, we could debate about last night’s debate all you want, but to me, there weren’t any clear winners. Well, actually, Elon Musk thinks there was a winner, but it wasn’t Trump or Biden.

–Aaron Bry & Nic Chahine

Today’s Price Action:

$SPY: -.39%
$QQQ: -.52%
$DIA: -.11%

Plus, check out the company that’s operating at the intersection of blockchain technology and artificial intelligence.

TODAY’S MOST VOLATILE STOCKS

TODAY’S TOP STORY

Inflation Reaches Over 3-Year Lows, Rate Cuts Are Getting Closer, Trump Dominates Debate: This Week In The Market

What Happened: The Federal Reserve's most closely monitored inflation measure — the Personal Consumption Expenditure price index — reached its lowest level since March 2021 in May, registering an annual rate of 2.6%, in line with economist expectations.

So: The inflation figures released Friday indicate that price pressures are trending toward the Fed's 2% target, solidifying market expectations for interest rate cuts. September is now seen as the most likely month for the first rate cut, followed by another by the end of the year, and potentially three more next year, according to market prediction data.

Basically: The first presidential debate concluded with a spike in Donald Trump's win probabilities to about 60%, as President Joe Biden's performance was widely viewed as disappointing. The odds of Biden being replaced have increased with just about four months left until the election. Here are the other top storylines from the week.

PRESENTED BY QLR

QRL Launches Project Zond Beta-Testnet For Blockchain Security In Quantum-Computing Era

Quantum computing is closer than ever to mainstream adoption, thrusting blockchain security to the forefront. In response, the Quantum Resistant Ledger (QRL) brings enterprise-level security to blockchain platforms, equipping them to operate in the quantum-computing era. QRL has recently introduced QRL Zond, a highly anticipated upgrade to its post-quantum secure distributed ledger technology (DLT). QRL Zond aims to ensure the protection of cryptocurrency transactions on the blockchain from the risks posed by massive quantum computers. As a result, developers can safely build next-gen applications in an environment with features and architecture native to the Ethereum blockchain. The QRL Zond feature is now available as beta-testnet version one.

ONE TRADE IDEA FOR NEXT WEEK

Nike Analysts Sour On Retailer's Short-Term Prospects Following Poor Outlook: 'No Quick Rebound'

Briefly: Nike shares plummeted following bleak revenue numbers and lowered guidance in its fourth-quarter report.

So: Some analysts have soured on the Beaverton, Oregon-based company. Here’s what the Street is saying Friday after the print.

The Nike Analysts: The following analysts published notes on Friday. JPMorgan analyst Matthew R. Boss downgraded Nike from Overweight to Neutral, lowering the price target from $116 to $83. Click here to see what the rest of the analysts are saying.

PRESENTED BY STARPAX

A New Cancer Treatment Conceived To Do What No Other Cancer Treatments Can

Current cancer treatments struggle to reach 90% of the tumor volume. Antibodies, nanocarriers, precision targeting medicine, and even immune cells, don’t reach more than 10% of the tumor volume. Join us in our mission to change the way we treat cancer. 

Here's why you should consider investing in Starpax’s patented technology:

• The future of cancer treatment is here: Starpax's cutting-edge technology features Starpax Living self-propelled Magnetodrones^TM, which are sensitive to special magnetic fields and carry drugs on their surface to the tumor volume. 

• Cutting-edge technology: The Living Magnetodrones, guided by the PolarTrak’s artificial intelligence, are injected directly into the tumor. Preclinical trials have demonstrated a 100% remission rate in extremely aggressive tumors without any side effects observed.

• Reduced risk, accelerated progress: Starpax minimizes trial risks and accelerates approvals with our FDA-approved anti-cancer molecules that can target six common cancers simultaneously. We meet the criteria for the FDA Fast Track Program and Health Canada accelerated review standards.

• Scalable business model: Partnering with top U.S. firms, Starpax plans rapid deployment of 25 treatment centers within seven years, with forecasted EBITDA reaching $12 billion annually upon FDA approval.
  

Invest in Starpax today and be part of this transformative journey.

BEFORE YOU GO

Were you forwarded this email? Click here to subscribe.

And be sure to check out our other newsletters:

Future Finance: Where fintech, crypto, and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.

Cannabis Daily: A must-read daily briefing for cannabis investors, operators, and enthusiasts. Join our list of industry veterans to jump start your morning. Subscribe here.

Real Estate Weekly: Where we highlight the movers and the losers, the upgrades and the downgrades, the top stories and opportunities in the trillion dollar REIT and real asset industry. Subscribe here.

Mining Weekly: Get an insider's edge with news, analysis, and commentary on what’s shaping the mining and commodities industry that powers the global economy. Subscribe here.